Scoop: Gilead out­lines plans to mus­cle up its man­u­fac­tur­ing arm af­ter Im­munomedics lay­offs

Gilead has had a no good, very bad week thus far. On Mon­day, the com­pa­ny re­vealed Phase III da­ta for its prized $21 bil­lion Im­munomedics drug that fell flat on Wall Street, and then Tues­day, re­ports first emerged that Gilead is plan­ning to lay off 114 staffers from Im­munomedics’ for­mer head­quar­ters — a move planned no lat­er than Feb­ru­ary but whose tim­ing co­in­ci­den­tal­ly proved un­for­tu­nate.

Now there’s a new shift to the nar­ra­tive in the works — which will in­clude some fu­ture hir­ing plans.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters